JPMorgan analyst Robbie Marcus noted that two separate short reports on iRhythm (IRTC) have been published this week, but he believes the arguments made in both are "unfounded and based upon false premises." The most recent short report asserts that competitor BioTelemetry (BEAT) is pushing for the American College of Cardiology to lower reimbursement or open up the Category III code earlier, but Marcus believe it is unlikely that a competitor could push the ACC to negotiate for lower reimbursement or a move to a new code ahead of schedule. He views today's report as "a slightly different take on the same flawed argument made by previous short reports," and would be a buyer of iRhythm shares amid the weakness. Marcus keeps an Overweight rating on iRhythm and reiterated the stock as a Top Pick.